[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks eased late Friday afternoon, with the NYSE Health Care Index down 0.1% and the He",
    "url": "https://finnhub.io/api/news?id=5f49b028de650a1dfcf36d9f9a966156bcc377d12e1e8a3761f7c168537bee37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743191733,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 133527543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks eased late Friday afternoon, with the NYSE Health Care Index down 0.1% and the He",
      "url": "https://finnhub.io/api/news?id=5f49b028de650a1dfcf36d9f9a966156bcc377d12e1e8a3761f7c168537bee37"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)",
    "summary": "Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D investments. Read what could be next for shares in this healthcare giant.",
    "url": "https://finnhub.io/api/news?id=7ba4c42e0d4508191cc139b945ea1be843422151fc91c492cfc1eb48c86e71af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743180023,
      "headline": "Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)",
      "id": 133524878,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D investments. Read what could be next for shares in this healthcare giant.",
      "url": "https://finnhub.io/api/news?id=7ba4c42e0d4508191cc139b945ea1be843422151fc91c492cfc1eb48c86e71af"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case",
    "summary": "A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.  U.S. District Judge Zahid Quraishi in Trenton, New Jersey, ordered the drugmaker's Janssen unit to pay $360 million for violating the federal False Claims Act.  He also imposed $1.28 billion in civil fines, or $8,000 for each of 159,574 false claims the jury found were submitted to programs such as Medicare, Medicaid and the AIDS Drug Assistance Program.",
    "url": "https://finnhub.io/api/news?id=6c30fa2046de27bc9bef6c24700301d957d14423255e86be97739552a2225301",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743178719,
      "headline": "Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case",
      "id": 133523773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.  U.S. District Judge Zahid Quraishi in Trenton, New Jersey, ordered the drugmaker's Janssen unit to pay $360 million for violating the federal False Claims Act.  He also imposed $1.28 billion in civil fines, or $8,000 for each of 159,574 false claims the jury found were submitted to programs such as Medicare, Medicaid and the AIDS Drug Assistance Program.",
      "url": "https://finnhub.io/api/news?id=6c30fa2046de27bc9bef6c24700301d957d14423255e86be97739552a2225301"
    }
  },
  {
    "ts": null,
    "headline": "J&J launches energy generator compatible with Ottava robot",
    "summary": "Johnson & Johnson said the Dualto energy system’s design allows for up to 46% less footprint than separate generators.",
    "url": "https://finnhub.io/api/news?id=940e05ddbe2132d460fd643f5dd989759cb08384e1450f45ad009fe6552b0298",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743172860,
      "headline": "J&J launches energy generator compatible with Ottava robot",
      "id": 133527544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson said the Dualto energy system’s design allows for up to 46% less footprint than separate generators.",
      "url": "https://finnhub.io/api/news?id=940e05ddbe2132d460fd643f5dd989759cb08384e1450f45ad009fe6552b0298"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25",
    "summary": "Danvers - Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella heart pump technology at the American College...",
    "url": "https://finnhub.io/api/news?id=9f441e27ecd16b80d8d3ce4ef830055df7f9045a481ffd2a79d2d0fd68fe8382",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743154890,
      "headline": "Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25",
      "id": 133508400,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Danvers - Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella heart pump technology at the American College...",
      "url": "https://finnhub.io/api/news?id=9f441e27ecd16b80d8d3ce4ef830055df7f9045a481ffd2a79d2d0fd68fe8382"
    }
  },
  {
    "ts": null,
    "headline": "2 Reasons to Like JNJ and 1 to Stay Skeptical",
    "summary": "Since September 2024, Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19.",
    "url": "https://finnhub.io/api/news?id=a1db944ed09fb42f65373dc37ed324cb2b299cc262456d49a399c2b0670b23bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743153117,
      "headline": "2 Reasons to Like JNJ and 1 to Stay Skeptical",
      "id": 133507755,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Since September 2024, Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19.",
      "url": "https://finnhub.io/api/news?id=a1db944ed09fb42f65373dc37ed324cb2b299cc262456d49a399c2b0670b23bd"
    }
  }
]